BMO Capital Upgrades ZIOPHARM Oncology (ZIOP) Two-Notches to Outperform; 'CAR-T Alliance Is Transformational'
Tweet Send to a Friend
BMO Capital upgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from Underperform to Outperform with a price target of $15.00 (from $1.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
